Zobrazeno 1 - 10
of 101
pro vyhledávání: '"C. A. Coltman"'
Autor:
A, Hoque, D, Albanes, S M, Lippman, M R, Spitz, P R, Taylor, E A, Klein, I M, Thompson, P, Goodman, J L, Stanford, J J, Crowley, C A, Coltman, R M, Santella
Publikováno v:
Cancer causescontrol : CCC. 12(7)
To conduct timely epidemiologic investigations of molecular/genetic markers that may contribute to the development of prostate, lung, colorectal, or other cancers within the Selenium and Vitamin E Cancer Prevention Trial (SELECT), and to evaluate int
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::b11d23b8b35a871a26464a6ccb2354d9
https://pubmed.ncbi.nlm.nih.gov/11552710
https://pubmed.ncbi.nlm.nih.gov/11552710
Autor:
William A. Knight, C. A. Coltman, Sarah A. Taylor, Laurence H. Baker, John S. Macdonald, John J. Constanzi, Phyllis J. Goodman
Publikováno v:
Investigational New Drugs. 8:S87-S89
Based on the high response rates seen among patients with colon cancer receiving high dose Melphalan with autologous marrow infusion, the Southwest Oncology Group conducted a Phase II trial of the compound at a conventional dose. The initial starting
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b5fb4d358311d3b22eae9729899647bb
https://doi.org/10.1007/bf00171991
https://doi.org/10.1007/bf00171991
Publikováno v:
The Prostate. 33(3)
A variety of innovative approaches to the prevention of prostate cancer are now available, including selenium, alpha tocopherol, dietary interventions, and vitamin D. Perhaps the most promising opportunity is based upon considerable evidence that cum
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::d02f62a4a0141663cdd8ed3008edbbf9
https://pubmed.ncbi.nlm.nih.gov/9365551
https://pubmed.ncbi.nlm.nih.gov/9365551
Publikováno v:
Oncology (Williston Park, N.Y.). 11(8)
The changing clinical dynamics of prostate cancer have resulted in a broadening of the research focus of the Genitourinary (GU) Cancer Committee of the Southwest Oncology Group (SWOG). Beginning with an emphasis on hormone-refractory disease in its e
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::ffb908ce453b529a11b3bc63ad85250e
https://pubmed.ncbi.nlm.nih.gov/9268978
https://pubmed.ncbi.nlm.nih.gov/9268978
Autor:
I M, Thompson, C A, Coltman
Publikováno v:
Seminars in urologic oncology. 14(2 Suppl 2)
Although early detection and treatment of prostate cancer is widely advocated, this so-called secondary prevention approach has a number of drawbacks. First, it is not yet certain that active treatment of localized prostate cancer offers any advantag
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::1eeb16f6cede82efa8d0b4327a5194db
https://pubmed.ncbi.nlm.nih.gov/8725886
https://pubmed.ncbi.nlm.nih.gov/8725886
Publikováno v:
Seminars in urology. 13(2)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::d4a487aee44955844b757813d7868479
https://pubmed.ncbi.nlm.nih.gov/7638469
https://pubmed.ncbi.nlm.nih.gov/7638469
Autor:
C A, Coltman
Publikováno v:
Seminars in oncology. 21(5 Suppl 10)
A large body of preclinical and clinical data concerning the new semisynthetic vinca alkaloid vinorelbine (Navelbine; Burroughs Wellcome Co, Research Triangle Park, NC; Pierre Fabre Médicament, Paris, France) are now available. At both the cellular
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::e45796b688d37a56a1ccf40956d2d001
https://pubmed.ncbi.nlm.nih.gov/7973763
https://pubmed.ncbi.nlm.nih.gov/7973763
Autor:
C A, Coltman
Publikováno v:
Seminars in oncology. 21(4 Suppl 7)
The Southwest Oncology Group has become a model for other oncology organizations in the way it facilitates participation of community physicians and their cancer patients in clinical trials. The Southwest Oncology Group accomplishes this through its
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::71be7a4aad9db18c59bbd91d33ccc928
https://pubmed.ncbi.nlm.nih.gov/8091235
https://pubmed.ncbi.nlm.nih.gov/8091235
Autor:
S. Dahlberg, Ellen R. Gaynor, Richard I. Fisher, E. M. Mize, Thomas P. Miller, M. M. Oken, T. M. Grogan, John H. Glick, C. A. Coltman
Publikováno v:
Annals of oncology : official journal of the European Society for Medical Oncology. 5
Summary Background CHOP is a four-drug, first-generation combination chemotherapy regimen that has cured approximately 30% of all patients with advanced stages of intermediate- or high-grade non-Hodgkin's lymphoma in national cooperative group trials
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::64cd8b3b904ac427afc7087d84f51f5e
https://pubmed.ncbi.nlm.nih.gov/7515652
https://pubmed.ncbi.nlm.nih.gov/7515652
Autor:
William A. Craig, R. G. Thomas, Robert D. Arbeit, T. T. Ward, J. B. Weinberg, R. L. Penn, C. A. Coltman, C. L. Fye, B. Chow, Sydney M. Finegold, J. Lentino, S. Ochi, B. W. Dana
Publikováno v:
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 17(3)
Despite widespread use of trimethoprim-sulfamethoxazole (TMP-SMZ) for prophylaxis in neutropenic patients, questions remain regarding its efficacy, toxicity, the risk of selection of resistant isolates, and the relation of its activity to selective d
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::da012fcff7b77e2e56daad002bc4dbd4
https://pubmed.ncbi.nlm.nih.gov/8218672
https://pubmed.ncbi.nlm.nih.gov/8218672